RYANODOL


Synonyms	Ryanodol
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	POSDEVOSMOCDHR-BPHXWNOMSA-N
Smiles	CC(C)[C@@]1(O)[C@@H](O)[C@@]2(O)[C@@]3(C)C[C@]4(O)O[C@@]5([C@H](O)[C@@H](C)CC[C@]35O)[C@@]2(O)[C@]14C
InChI	InChI=1S/C20H32O8/c1-9(2)17(25)12(22)18(26)13(4)8-16(24)14(17,5)20(18,27)19(28-16)11(21)10(3)6-7-15(13,19)23/h9-12,21-27H,6-8H2,1-5H3/t10-,11+,12+,13-,14-,15-,16-,17+,18+,19+,20+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H32O8
Molecular Weight	400.46
AlogP	-1.58
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	7.0
Number of Rotational Bond	1.0
Polar Surface Area	150.84
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	28.0

Assay Description	Organism	Bioactivity
Toxicity against Blattella germanica (German cockroach) assessed as immobility	Blattella germanica	1.0 ug/g
Toxicity against SCR-susceptible Musca domestica (house fly) assessed as immobility compound administered by intrathoracic injection measured 4 hr post compound treatment	Musca domestica	1.1 ug/g
Ratio of compound KD50 to ryanodine KD50 for Blattella germanica (German cockroach) assessed as immobility	Blattella germanica	2.0
Ratio of compound KD50 to ryanodine KD50 for SCR-susceptible Musca domestica (house fly) assessed as immobility compound administered by intrathoracic injection measured 4 hr post compound treatment	Musca domestica	0.8
Ratio of compound LC50 to ryanodine LC50 for ip dosed Mus musculus Swiss-Webster (mouse) assessed as mortality measured after 24 hr	Mus musculus	200.0
Ratio of compound KD50 to ryanodine KD50 for SCR-susceptible Musca domestica (house fly) assessed as immobility compound administered by intrathoracic injection 2 hr after piperonyl butoxide treatment measured 4 hr post compound treatment	Musca domestica	3.6
Ratio of compound IC50 to ryanodine IC50 for Ca2+-ryanodine receptor in Oryctolagus cuniculus (rabbit) skeletal muscle sarcoplasmic reticulum after 80 min by competitive inhibition assay	Oryctolagus cuniculus	3500.0
Toxicity against SCR-susceptible Musca domestica (house fly) assessed as immobility compound administered by intrathoracic injection 2 hr after piperonyl butoxide treatment measured 4 hr post compound treatment	Musca domestica	0.34 ug/g
Toxicity in ip dosed Mus musculus Swiss-Webster (mouse) assessed as mortality measured after 24 hr	Mus musculus	20.0 mg.kg-1
Displacement of [3H]ryanodine from Ca2+-ryanodine receptor in Oryctolagus cuniculus (rabbit) skeletal muscle sarcoplasmic reticulum after 80 min by competitive inhibition assay	Oryctolagus cuniculus	35000.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL518689
PubChem	14588813

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).